Table 2 FAZ parameters, CST, and BCVA at baseline, month 1, month 3, and month 6 following intravitreal anti-VEGF therapy
Parameter | Baseline | Month 1 | Month 3 | Month 6 | p value |
|---|---|---|---|---|---|
FAZ in SCP | |||||
Area (mm2) | 0.46 ± 0.29 | 0.48 ± 0.20 | 0.48 ± 0.20 | 0.44 ± 0.17 | 0.772 |
Perimeter (mm) | 3.08 ± 0.95 | 3.24 ± 0.81 | 3.40 ± 1.44 | 3.13 ± 0.89 | 0.405 |
Circularity | 0.61 ± 0.08 | 0.62 ± 0.08 | 0.64 ± 0.08 | 0.64 ± 0.08 | 0.157 |
FAZ in DCP | |||||
Area (mm2) | 0.81 ± 0.27 | 0.83 ± 0.16 | 0.84 ± 0.18 | 0.79 ± 0.16 | 0.620 |
Perimeter (mm) | 3.71 ± 1.30 | 3.85 ± 0.97 | 3.95 ± 1.22 | 3.83 ± 1.12 | 0.769 |
Circularity | 0.75 ± 0.18 | 0.74 ± 0.18 | 0.73 ± 0.17 | 0.70 ± 0.16 | 0.481 |
CST (μm) | 367.00 ± 121.81 | 323.65 ± 83.32 | 302.08 ± 49.51 | 292.17 ± 58.83 | < 0.001 |
BCVA (ETDRS) | 60.40 ± 19.85 | 63.35 ± 19.87 | 67.92 ± 19.48 | 72.94 ± 14.92 | 0.004 |